PubMed Health⌕ Search

Biomedical subjects

Hong Ren

Publications and source records attributed to Hong Ren.

At least 37 records · Page 2Linked to original sources
PubMed2006

[An analysis of articles published from 1996-2005 in the Chinese Journal of Hepatology (Zhonghua Ganzangbing Zazhi].

OBJECTIVE: To study the academic level, subject location, influence, readership, degree of usage and recognition by the readers of the Chinese Journal of Hepatology. METHODS: By referring to the "Chinese & T Journal Citation Reports" edited by the Institute of Scientific and Technical Information of China, the numbers, types, pertinent diseases, funding statues, citing, and the intervals between receiving and the publication of all the articles published in the 72 issues of the Chinese Journal of Hepatology were statistically analyzed. The work units and the geographic locations of the authors were also analyzed. RESULTS: During the past ten years, 2,437 articles were published, 27.4 percent of the total received. Of the published articles 892 were on viral hepatitis (36.6%), 428 on liver fibrosis or cirrhosis (17.6%), 421 on liver cancer (17.3%), and 696 on other subjects (28.6%). The impact factor and the total cited numbers of the articles of the journal were among the top five in the profession. Some other reference indexes used to evaluate the periodicals of the journal were better than average level of other periodicals in China. The number of references of each original article in this journal averaged 4.6, most of which were English ones. The average number of the authors of each articles were 4.5, and 89.7 percent of all the articles were written by two authors. Only one article was from an American author (first author), and the others first authors were all from 31 provinces, main cities and PLA institutions in China. Of the total 2,437 articles, 71.7% (1,744) were from the following: Chongqing (387), Shanghai (381), Beijing (315), Guangdong (227), PLA institutions (212), Zhejiang (115), and Hubei (107). CONCLUSION: The Chinese Journal of Hepatology is a periodical which has been highly regarded by professionals and has a great influence in academic fields.

Bibliometrics↗
PubMed2006

[Citation analysis of the Chinese Journal of Hepatology (Zhonghua Ganzangbing Zazhi) in the year 2005].

OBJECTIVE: To evaluate the academic level and the popularity of the Chinese Journal of Hepatology in China in 2005. METHODS: We used bibliometrics to analyze statistically the original articles of the Chinese Journal of Hepatology cited by Chinese periodicals included in the Wanfang Data in 2005. RESULTS: (1) 699 published papers in the journal in 2005 were cited 1673 times and 44 of them were cited 720 times in total. (2) The papers published in the Chinese Journal of Hepatology were cited by journals in China starting from 1993 through 2005. Of all the cited articles, 1.49% of them were cited in the same year as they were published. (3) Non-specific rate of the Chinese Journal of Hepatology was 96.17%, and self-cite rate was 3.83%. (4) Papers published in the Chinese Journal of Hepatology were cited by 400 Chinese periodicals, 99 of them are journals included in the Chinese Science Citation Database, and 110 of them are Chinese core periodicals. CONCLUSION: The Chinese Journal of Hepatology is one of the high level academic Chinese periodicals. This journal reflects the progress in research on liver diseases in China.

Bibliometrics↗
PubMed2006

[Immunogenicity of chimeric gene vaccine Mtb8.4/hIL12].

AIM: To construct chimeric gene vaccine Mtb8.4/hIL-12, express it in COS-7 cells and study its immunogenicity. METHODS: Chimeric gene Mtb8.4/hIL-12 was amplified by PCR and cloned into the eukaryotic vector pCI-neo to construct the recombinant plasmid pCI-neo-Mtb8.4/hIL12. After the recombinant plasmid was identified by restriction enzyme digestion analysis, PCR and DNA sequencing, COS-7 cells were transfected with pCI-neo-Mtb8.4/hIL12 through cationic liposome. 48 hours later, the expression of mRNA was detected by RT-PCR and the level of hIL-12 in culture supernatant and cell lysates were detected by Western blot. C57BL/6N mice were vaccinated with chimeric gene vaccine Mtb8.4/hIL-12 three times at the interval of 3 weeks each time. Four weeks after the final inoculation, three mice were sacrificed to assess the cytotoxicity of CTLs and response to cytokine. RESULTS: The recombinant plasmid pCI-neo-Mtb8.4/hIL12 was constructed successfully. After COS-7 cells were transfected with pCI-neo-Mtb8.4/hIL12, chimeric gene Mtb8.4/hIL12 was expressed in COS-7 cells. The chimeric gene vaccine could induce strong antigen-specific immune response. With the increase of IFN-gamma and IL-2 secretion and the decrease of IL-4 secretion, the cytotoxicity of specific CTLs was heightened. CONCLUSION: Recombinant plasmid pCI-neo-Mtb8.4/hIL12 has been successfully constructed and expressed in COS-7 cells. The constructed chimeric gene vaccine Mtb8.4/hIL12 is of strong immunogenicity and can obviously induce the cytotoxicity of CTLs.

Animals↗
PubMed2005

A Quasi species of the pre-S/S gene and mutations of enhancer II/core promoter/pre-C in mothers and their children infected with hepatitis B virus via mother-to-infant transmission.

BACKGROUND: Hepatitis B virus (HBV) infection has a tendency to be chronic. The quasi species of HBV in the pre-S/S gene and mutations in enhancer II (EnhII)/core promoter (CP)/pre-C of HBV were studied in asymptomatic carrier (AsC) mothers and their children with different virus loads, to gain a better understanding of the pathogenic mechanisms of HBV. METHODS: Quasi species were analyzed using an established phylogenetic tree based on the sequences of the pre-S/S gene from 3 mother-child pairs. The mutations of EnhII/CP/pre-C were studied in 15 mother-child pairs. RESULTS: Substitution was the main mutation model. The phylogenetic tree indicated that the pre-S/S gene in every mother-child pair had the same root. The sequences of the pre-S/S gene of each patient were somewhat different from one another, but there was limited evolutionary distance between them. The evolutionary distances between the pre-S/S gene and the base of the tree in patients with low virus loads were greater than those in patients with high virus loads. The mutations in patients with low virus loads were much more frequent than those in patients with high virus loads and were not related to age, irrespective of whether the pre-S/S gene or EnhII/CP/pre-C was considered. CONCLUSIONS: There are HBV quasi species in the sera of AsCs, and the mutations are related to virus load and hepatitis B e antigen seroconversion, irrespective of age.

Adult↗
PubMed2005

The immunogenicity and protective efficacy of Mtb8.4/hIL-12 chimeric gene vaccine.

DNA vaccination has emerged as a powerful approach in the search for a more efficacious vaccine against tuberculosis (TB). In this study, we evaluated the immunogenicity and protective efficacy of Mtb8.4/hIL-12 chimeric gene vaccine. The Mtb8.4/hIL-12 chimeric gene was amplified by PCR and cloned into the eukaryotic expression vector pCI-neo. C57BL/6N mice were vaccinated with Mtb8.4/hIL-12 chimeric gene vaccine for three times at 3 weeks intervals. Four weeks after the final inoculation, three mice per group were sacrificed to assess cytokine response and CTL induction and the other five mice per group were challenged intravenously in a lateral tail vein with 1 x 10(6) CFU of virulent Mycobacterium tuberculosis H37Rv. Spleen and the left lung were harvested from each mouse at 4 weeks after infection and homogenized in sterile saline. Serial dilutions of organ homogenates were plated on L-J agar and incubated 37 degrees C until colonies were visible 4 weeks later. Protective efficacies in each experiment were expressed as reduced CFU and were compared with the negative control group. The right lung was obtained from each mouse and immediately inflated with and stored in 10% formalin saline. Tissues were embedded in paraffin, sectioned and stained with hematoxylin and eosin. Mtb8.4/hIL-12 chimeric gene vaccine induced the secretion of more of Th1 cytokines, but not IL-4 and enhanced CTL activity. Mice immunized with Mtb8.4/hIL-12 chimeric gene vaccine had fewer and smaller tubercles than control groups. As expected, control mice had the highest bacterial loads in both lung and spleen. Immunization with Mtb8.4/hIL-12 chimeric gene vaccine could remarkably reduced CFU counts in organs. When it was used to construct the chimeric gene vaccine, hIL-12 could improve the immune efficacy of Mtb8.4 gene vaccine.

Animals↗
PubMed2005

Replication of hepatitis B virus in primary duck hepatocytes transfected with linear viral DNA.

AIM: To explore the expression and replication of hepatitis B virus (HBV) DNA in primary duck hepatocytes (PDHs). METHODS: Complete HBV genome was transfected into PDHs by electroporation (transfected group, 1.19 x 10(12) copies of linear HBV DNA/1 x 10(7) PDHs). After 1-5 d of transfection, HBsAg and HBeAg in the supernatant and lysate of PDHs were measured with the IMX System. Meanwhile, replicative intermediates of HBV DNA were analyzed by Southern blotting and Dot blotting. PDHs electroporated were used as control group. RESULTS: HBsAg in the hepatocyte lysates of transfected group was 15.24 (1 d), 14.55 (3 d) and 5.13 (5 d; P/N values, positive > or =2.1) respectively. HBeAg was negative (<2.1). Both HBsAg and HBeAg were negative in the supernatant of transfected group. Dot blotting revealed that HBV DNA was strongly positive in the transfected group and negative in the control group. Southern blot analysis of intracellular total DNA indicated that there were relaxed circular (rc DNA), covalently closed circular (ccc DNA), and single-stranded (ss DNA) HBV DNA replicative intermediates in the transfected group, there was no integrated HBV DNA in the cellular genome. These parameters were negative in control group. CONCLUSION: Expression and replication of HBV genes can occur in hepatocytes from non-mammalian species. HBV replication has no critical species-specificity, and yet hepatic-specific regulating factors in hepatocytes may be essential for viral replication.

Animals↗
PubMed2005

Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study.

AIM: To investigate the therapeutic effect of autologous HBsAg-loaded dendritic cells (DCs) on patients with chronic hepatitis B. METHODS: Monocytes were isolated from fresh peripheral blood of 19 chronic HBV-infected patients by Ficoll-Hypaque density gradient centrifugation and cultured by plastic-adherence methods. DCs were induced and proliferated in the culture medium with recombinant human granulocyte-macrophage-colony-stimulating factor (rhGM-CSF) and human interleukin-4 (rhIL-4). DCs pulsed with HBsAg for twelve hours were injected into patients subcutaneously twice at intervals of two weeks. Two patients received 100 mg oral lamivudine daily for 12 mo at the same time. HBV-DNA and viral markers in sera of patients were tested every two months. RESULTS: By the end of 2003, 11 of 19 (57.9%) patients had a clinical response to DC-treatment. HBeAg of 10 (52.6%) patients became negative, and the copies of HBV-DNA decreased 10(1.77+/-2.39) on average (t = 3.13, P<0.01). Two cases co-treated with DCs and lamivudine had a complete clinical response. There were no significant differences in the efficient rate between the cases with ALT level lower than 2XULN and those with ALT level higher than 2XULN before treatment (chi(2) = 0.0026). CONCLUSION: Autologous DC-vaccine induced in vitro can effectively suppress HBV replication, reduce the virus load in sera, eliminate HBeAg and promote HBeAg/anti-HBe transformation. Not only the patients with high serum ALT levels but also those with normal ALT levels can respond to DC vaccine treatment, and the treatment combining DCs with lamivudine can eliminate viruses more effectively.

Adolescent↗
PubMed2005

[An in vitro study of specific antitumor immunity induced by dendritic cells pulsed with tumor cell lysates from patients with hepatocellular carcinoma].

OBJECTIVE: To investigate T cell-mediated antitumor effects of dendritic cells (DCs) pulsed with tumor lysates in patients with hepatocellular carcinoma (HCC) in vitro. METHODS: DCs isolated from peripheral blood mononuclear cells of HCC patients were cultured and proliferated in vitro by using recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) and interleukin-4 (rhIL-4), and then were pulsed with autologous hepatoma cell lysates. The phenotypes of the DCs were assayed by flow cytometry. The concentration of IFN-gamma and IL-12 were measured in culture supernatants by ELISA. The ability of DCs pulsed with hepatoma cell lysates to stimulate proliferation of autologous T lymphocytes (CTL) was tested by thymidine incorporation method. The specific cytolytic activity of CTL was assessed by MTT method. RESULTS: The hepatoma cell lysates pulsed DC vaccines led to up-regulation of CD1a, CD40, CD86 and HLA-DR. Concentrations of IFN-gamma and IL-12 were increased more in the hepatoma cell lysate pulsed DCs group than those in the unpulsed DCs group, the hepatoma cell lysate group and control group. The proliferation of T-cells was markedly enhanced in the hepatoma cell lysate pulsed DCs group than that in the others. The CTL stimulated by the hepatoma cell lysate pulsed DCs had much higher cytotoxicity to autologous hepatoma cells (killing rate: 81.72%+/-9.49%), as compared with HepG2 and HNE-1 tumor cells (killing rate: 49.37%+/-11.21% and 17.14%+/-5.65%, respectively). CONCLUSION: The hepatoma cell lysate pulsed DC vaccines can induce an effective and specific anti-hepatoma effect.

Adult↗
PubMed2005

[Comprehensive evaluation of the Chinese Journal of Hepatology (Zhonghua Ganzangbing Zazhi) from 1999 to 2003].

OBJECTIVE: The Chinese Journal of Hepatology is a key journal in the research field of liver diseases in China. Ranked by the impact factor, which was issued and used by the Institute of Scientific and Technical Information of China, it is in fourth position among medical journals in China. In order to evaluate the journal, some facts about it were surveyed, including the number of pages, the number of papers in each issue, organizations of the authors, funding for their works, the impact factor, immediacy index, statuses of the articles' references, and a listing of their being cited. METHODS: The number of pages of each issue, the number of papers in every volume, and citations were quantitatively analyzed. Funding, impact factor, immediacy index, citations and organizations of the authors were analyzed by weighted Rank Sum Ratio (RSRw). RESULTS: In the five years, 1999, 2000, 2001, 2002, and 2003, (1) The Chinese authors came from 26 of the 31 provinces and cities in China. 48.8% in 1999 to 71.7% in 2003 of the authors were working in medical universities or medical colleges, and some authors were overseas experts. (2) The number of articles cited in the five years were 702, 1158, 1087, 1178 and 1744. (3) The number of papers published were 248, 221, 242, 212 and 336. (4) Impact factors of the journal were 0.897, 0.931, 1.421, 1.858, 1.440. With the cites, immediacy index, cited rate, ratios of research provided by national or international funds and number of organizations of authors evaluated, the RSRw results of the five years were 0.2750, 0.3417, 0.5000, 0.5000 and 0.5000. CONCLUSION: The Chinese Journal of Hepatology is well-known and is one of the highest academic quality medical journals in China. It reflects the progress of liver disease research in China.

Biometry↗
PubMed2005

[Clinical effects of dendritic cells pulsed with autologous hepatoma cell lysates on the postoperative recurrence and metastasis of hepatocellular carcinoma].

OBJECTIVE: To investigate clinical effects of dendritic cells (DCs) pulsed with autologous hepatoma cell lysates on postoperative recurrence and metastasis of hepatocellular carcinoma (HCC). METHODS: DCs isolated from peripheral blood mononuclear cells of HCC patients were cultured and propagated in vitro using rhGM-CSF and rhIL-4, and then were pulsed with autologous hepatoma cell lysates. Thirty postoperative patients with HCC were randomly divided into two groups. Fifteen cases were treated with DC vaccine; fifteen cases received chemotherapy only as a control group. Immune function, clinical effects, hepatic tumor recurrence rate and the survival rate of patients of the two groups were observed and compared. RESULTS: The levels of CD3+, CD4+/CD8+ and NK cells in the DC vaccine group were significantly increased after vaccination, while those of the control group had no significant changes. The concentration of IL-10 in the DC vaccine group was significantly decreased after the vaccination (P < 0.05). The hepatic tumor recurrence rate at 18 months in the DC vaccine group was 13.33%, compared with 53.33% in the control group (P < 0.05). The survival rate in the former was 93.33%, compared with that of 60% in the later (P < 0.05). CONCLUSION: Hepatoma cell lysates pulsed DC vaccine may improve the immune function of the postoperative HCC patients and play an important role in prevention of postoperative recurrence and metastasis of HCC, which would provide an innovative approach for the immunotherapy of HCC.

Cancer Vaccines↗
PubMed2005

[Cloning of CTB-PROIN fusion gene and its expression in Escherichia coli].

A fusion gene CTB-PROIN, in which Proinsulin gene was fused to the 3' end of CTB gene by a hinge peptide 'GPGP', was constructed and cloned into pET-30a(+) to obtain a prokaryotic expression vector pETCPI. Subsequently the recombinant plasmid pETCPI was transformed into E. coli stain BL21 (DE3). After induced by IPTG, the expression product was analyzed by sodium dodecyl sulphate-polyacrylamide gel (15%) electrophoresis (SDS-PAGE), and its result indicated that the recombinant protein CTB-PROIN was expressed and accumulated as inclusion bodies. The recombinant CTB-PROIN protein accumulated to the level of 25% of total bacterial proteins. After inclusion bodies was denaturalized and refolded in vitro, significant assembly of monomers had occurred, and the recombinant protein represented assembled pentamers. The results of western blotting analysis also demonstrated that the fusion protein could be recognized by the anti-CT and anti-insulin antibody, respectively. In addition, the result of the CTB-PROIN-GM1 binding assay, that the protein could bind to monosialoganglioside specifically, showed it possesed biological activity in vitro. These results provided the possibility of developing a cheaper and more efficient oral vaccine for type I diabetes using such constructs.

Artificial Gene Fusion↗
PubMed2005

[Clinical investigation of famciclovir in chronic hepatitis B patients irresponsive to alpha interferon treatment].

OBJECTIVES: To evaluate the efficacy and safety of famciclovir on the decreasing levels of serum HBV-DNA and ALT and HBeAg/antiHBe seroconversion in chronic hepatitis B patients irresponsive to 3 months treatment with alpha interferon. METHODS: Two hundred and nineteen patients with chronic HBV infection, defined as positive HBsAg, HBeAg and HBV DNA, were enrolled and randomly half-and- half put into famciclovir and placebo groups. The two groups received either famciclovir 500 mg tid or a placebo treatment for 24 weeks, and then were followed-up for another 24 weeks with no treatment. RESULTS: At the end of 24 weeks, the log value of HBV DNA dropped from 6.54+/-1.26 to 5.70+/-2.03 in the famciclovirt group and were elevated from 6.30+/-1.32 to 6.51+/-1.65 in the placebo group (P < 0.01). The rate of cases with persistence HBV DNA dropped 2 log of quantity in the famciclovir group and was 28.28% (28/99); it was 9.47% (9/95) in the placebo group (P < 0.01). Those with persistence negative HBV DNA was 28.28% (28/99) in the flamciclovir treated group and 14.74% (14/95) in the placebo group (P < 0.05). Those persistently being HBeAg negative were 7.69% (7/91) in the famciclovir treated group and 3.33% (3/90) in the placebo group (P > 0.05). The HBeAg/antiHBe seroconversion was 4.40% (4/91) in the famciclovir group and 2.22% (2/90) in the placebo group (P > 0.05). The percentage of cases with normal of ALT level was 15.15% in the famciclovir group and 6.35% in the placebo group (P < 0.05). CONCLUSION: Famciclovir is effective in inhibiting HBV DNA replication and in decreasing serum ALT levels. The rate of HBeAg/antiHBe seroconversion in the famciclovir treated group was similar to that of the placebo group. Famciclovir was well tolerated without severe adverse effects during our treatment.

2-Aminopurine↗
PubMed2005

[Experimental gene therapy mediated by fractalkine (FK) for murine liver cancer].

OBJECTIVES: Chemokines play an important role in the infiltration of immune cells into tumor tissues. Anti-tumor immune response has been elicited in many tumor models by chemokine gene transfection. The aim of this study was to evaluate the possibility of inducing anti-hepatocellular carcinoma active immune response by transfection of mouse hepatocellular carcinoma cells MM45T.Li with chemokine FK gene. METHODS: Mouse FK gene was transduced into mouse hepatocellular carcinoma cells MM45T.Li using of liposome.G418-resistant clones were selected and the FK mRNA expression was detected by RT-PCR. In vivo experiments were performed to observe the tumorigenicity of wild type MM45T.Li and FK gene modified tumor cells. The immune cell infiltration in tumor tissues was detected histopathologically. The level of CD4+ and CD8+ T cells in peripheral blood were detected by FACS. RESULTS: RT-PCR detection showed that FK was expressed in FK gene transfected G418-resistant clones (MM45T.Li-FK), but not in the wild type MM45T.Li. In vivo experiments the tumorigenicity of MM45T.Li-FK had decreased compared to the wild type MM45T.Li. In the tumor tissues from MM45T.Li-FK, many infiltrated immune cells were found, but few immune cells infiltrated into the tumor tissues from the controls. The level of CD4+ and CD8+ T cells had obviously increased in MM45T.Li-FK compared to the controls (P < 0.01). CONCLUSION: Transfection with chemokine FK gene can induce anti-hepatocellular carcinoma active immune response.

Animals↗